Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers

Pantel, Austin R.; Mankoff, David A.

doi:10.1016/j.canlet.2016.05.008

Title: Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers

Journal Article · Mon May 16 00:00:00 EDT 2016 · Cancer Letters

DOI:https://doi.org/10.1016/j.canlet.2016.05.008· OSTI ID:1462353

^[1]; Mankoff, David A. ^[1]

Univ. of Pennsylvania, Philadelphia, PA (United States). Perelman School of Medicine, Dept. of Radiology and Division of Nuclear Medicine and Molecular Imaging

Molecular imaging agents have the ability to non-invasively visualize, characterize, and quantify the molecular biology of disease. Recent advances in nuclear probe development, particularly in PET radiotracers, have generated many new imaging agents with precise molecular targets. With such specificity, PET probes may be utilized as biomarkers to objectively interrogate and evaluate pathology. Whereas the current indications for PET imaging are predominately confined to staging and restaging of malignancy, the utility of PET greatly expands when utilized as a biomarker, the topic of this review. As an imaging biomarker, PET may be used to (1) measure target expression to select subsets of patients who would most benefit from targeted therapy; (2) measure early treatment response to predict therapeutic efficacy; and (3) relate tumor response to survival. This work will discuss the application of radiotracers to targeted cancer therapy. Particular attention is given to new radiotracers evaluated in recently completed clinical trials and those with current or potential clinical utility. The diverse roles of PET in clinical trails for drug development are also examined.

View Accepted Manuscript (DOE)

View Accepted Manuscript (Publisher)

Cite

Export

Save

Research Organization:: Univ. of Pennsylvania, Philadelphia, PA (United States)

Sponsoring Organization:: USDOE; Susan G. Komen Foundation; National Institutes of Health (NIH)

Grant/Contract Number:: SC0012476; AC140060; U01-CA19025; U01-CA148131

OSTI ID:: 1462353

Alternate ID(s):: OSTI ID: 1414471

Journal Information:: Cancer Letters, Vol. 387, Issue C; ISSN 0304-3835

Publisher:: ElsevierCopyright Statement

Country of Publication:: United States

Language:: English

Citation Metrics:

Cited by: 15 works

Citation information provided by
Web of Science

References (87)

How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy Farwell, Michael D.; Clark, Amy S.; Mankoff, David A. JAMA Oncology, Vol. 1, Issue 4 https://doi.org/10.1001/jamaoncol.2015.0667	journal	July 2015
Momentum grows to make 'personalized' medicine more 'precise' Katsnelson, Alla Nature Medicine, Vol. 19, Issue 3 https://doi.org/10.1038/nm0313-249	journal	March 2013
Molecular Imaging Research in the Outcomes Era Mankoff, David A.; O’Sullivan, Finbarr; Barlow, William E. Academic Radiology, Vol. 14, Issue 4 https://doi.org/10.1016/j.acra.2007.01.005	journal	April 2007
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eisenhauer, E. A.; Therasse, P.; Bogaerts, J. European Journal of Cancer, Vol. 45, Issue 2 https://doi.org/10.1016/j.ejca.2008.10.026	journal	January 2009
Molecular imaging in living subjects: seeing fundamental biological processes in a new light Massoud, T. F. Genes & Development, Vol. 17, Issue 5 https://doi.org/10.1101/gad.1047403	journal	March 2003
An introduction to functional and molecular imaging with MRI Gallagher, F. A. Clinical Radiology, Vol. 65, Issue 7 https://doi.org/10.1016/j.crad.2010.04.006	journal	July 2010
Molecular magnetic resonance imaging Hengerer, A.; Grimm, J. Biomedical Imaging and Intervention Journal, Vol. 2, Issue 2 https://doi.org/10.2349/biij.2.2.e8	journal	January 2006
Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications Soares, D. P.; Law, M. Clinical Radiology, Vol. 64, Issue 1 https://doi.org/10.1016/j.crad.2008.07.002	journal	January 2009
Clinical Imaging of Tumor Metabolism with 1 H Magnetic Resonance Spectroscopy Martín Noguerol, Teodoro; Sánchez-González, Javier; Martínez Barbero, José Pablo Magnetic Resonance Imaging Clinics of North America, Vol. 24, Issue 1 https://doi.org/10.1016/j.mric.2015.09.002	journal	February 2016
Ultrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics Kiessling, F.; Fokong, S.; Koczera, P. Journal of Nuclear Medicine, Vol. 53, Issue 3 https://doi.org/10.2967/jnumed.111.099754	journal	March 2012
Molecular imaging with targeted contrast ultrasound Kaufmann, Beat A.; Lindner, Jonathan R. Current Opinion in Biotechnology, Vol. 18, Issue 1 https://doi.org/10.1016/j.copbio.2007.01.004	journal	February 2007
Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics Hellebust, Anne; Richards-Kortum, Rebecca Nanomedicine, Vol. 7, Issue 3 https://doi.org/10.2217/nnm.12.12	journal	March 2012
Optical contrast agents and imaging systems for detection and diagnosis of cancer Pierce, Mark C.; Javier, David J.; Richards-Kortum, Rebecca International Journal of Cancer, Vol. 123, Issue 9 https://doi.org/10.1002/ijc.23858	journal	November 2008
PET versus SPECT: strengths, limitations and challenges Rahmim, Arman; Zaidi, Habib Nuclear Medicine Communications, Vol. 29, Issue 3 https://doi.org/10.1097/MNM.0b013e3282f3a515	journal	January 2008
Is there still a role for SPECT–CT in oncology in the PET–CT era? Hicks, Rodney J.; Hofman, Michael S. Nature Reviews Clinical Oncology, Vol. 9, Issue 12 https://doi.org/10.1038/nrclinonc.2012.188	journal	November 2012
Absolute quantification in SPECT Ritt, Philipp; Vija, Hans; Hornegger, Joachim European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue S1 https://doi.org/10.1007/s00259-011-1770-8	journal	April 2011
Molecular Imaging Biomarkers for Oncology Clinical Trials Mankoff, David A.; Pryma, Daniel A.; Clark, Amy S. Journal of Nuclear Medicine, Vol. 55, Issue 4 https://doi.org/10.2967/jnumed.113.126128	journal	March 2014
Missed Breast Cancers at US-guided Core Needle Biopsy: How to Reduce Them Youk, Ji Hyun; Kim, Eun-Kyung; Kim, Min Jung RadioGraphics, Vol. 27, Issue 1 https://doi.org/10.1148/rg.271065029	journal	January 2007
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer Hammond, M. Elizabeth H.; Hayes, Daniel F.; Dowsett, Mitch Journal of Clinical Oncology, Vol. 28, Issue 16 https://doi.org/10.1200/JCO.2009.25.6529	journal	June 2010
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression Lindström, Linda Sofie; Karlsson, Eva; Wilking, Ulla M. Journal of Clinical Oncology, Vol. 30, Issue 21 https://doi.org/10.1200/JCO.2011.37.2482	journal	July 2012
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Van Poznak, Catherine; Somerfield, Mark R.; Bast, Robert C. Journal of Clinical Oncology, Vol. 33, Issue 24 https://doi.org/10.1200/JCO.2015.61.1459	journal	August 2015
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Kuukasjärvi, T.; Kononen, J.; Helin, H. Journal of Clinical Oncology, Vol. 14, Issue 9 https://doi.org/10.1200/JCO.1996.14.9.2584	journal	September 1996
Breast cancer: PET imaging of estrogen receptors. Mintun, M. A.; Welch, M. J.; Siegel, B. A. Radiology, Vol. 169, Issue 1 https://doi.org/10.1148/radiology.169.1.3262228	journal	October 1988
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸ F-Fluoroestradiol Peterson, Lanell M.; Mankoff, David A.; Lawton, Thomas Journal of Nuclear Medicine, Vol. 49, Issue 3 https://doi.org/10.2967/jnumed.107.047506	journal	February 2008
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer Mortimer, Joanne E.; Dehdashti, Farrokh; Siegel, Barry A. Journal of Clinical Oncology, Vol. 19, Issue 11 https://doi.org/10.1200/JCO.2001.19.11.2797	journal	June 2001
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer Linden, Hannah M.; Stekhova, Svetlana A.; Link, Jeanne M. Journal of Clinical Oncology, Vol. 24, Issue 18 https://doi.org/10.1200/JCO.2005.04.3810	journal	June 2006
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Dehdashti, Farrokh; Mortimer, Joanne E.; Trinkaus, Kathryn Breast Cancer Research and Treatment, Vol. 113, Issue 3 https://doi.org/10.1007/s10549-008-9953-0	journal	March 2008
A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC) Peterson, Lanell M.; Kurland, Brenda F.; Schubert, Erin K. Molecular Imaging and Biology, Vol. 16, Issue 3 https://doi.org/10.1007/s11307-013-0699-7	journal	October 2013
Hypoxia — a key regulatory factor in tumour growth Harris, Adrian L. Nature Reviews Cancer, Vol. 2, Issue 1 https://doi.org/10.1038/nrc704	journal	January 2002
Hypoxia, gene expression, and metastasis Chan, Denise A.; Giaccia, Amato J. Cancer and Metastasis Reviews, Vol. 26, Issue 2 https://doi.org/10.1007/s10555-007-9063-1	journal	April 2007
Hypoxia in cancer: significance and impact on clinical outcome Vaupel, Peter; Mayer, Arnulf Cancer and Metastasis Reviews, Vol. 26, Issue 2 https://doi.org/10.1007/s10555-007-9055-1	journal	April 2007
Hypoxic Radiosensitization: Adored and Ignored Overgaard, Jens Journal of Clinical Oncology, Vol. 25, Issue 26 https://doi.org/10.1200/JCO.2007.12.7878	journal	September 2007
Molecular Imaging of Hypoxia Chitneni, Satish K.; Palmer, Gregory M.; Zalutsky, Michael R. Journal of Nuclear Medicine, Vol. 52, Issue 2 https://doi.org/10.2967/jnumed.110.075663	journal	January 2011
Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Yang, D. J.; Wallace, S.; Cherif, A. Radiology, Vol. 194, Issue 3 https://doi.org/10.1148/radiology.194.3.7862981	journal	March 1995
Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) Rischin, Danny; Peters, Lester; Fisher, Richard Journal of Clinical Oncology, Vol. 23, Issue 1 https://doi.org/10.1200/JCO.2005.01.072	journal	January 2005
Prognostic Significance of [ ¹⁸ F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 Rischin, Danny; Hicks, Rodney J.; Fisher, Richard Journal of Clinical Oncology, Vol. 24, Issue 13 https://doi.org/10.1200/JCO.2005.05.2878	journal	May 2006
Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group Rischin, Danny; Peters, Lester J.; O'Sullivan, Brian Journal of Clinical Oncology, Vol. 28, Issue 18 https://doi.org/10.1200/JCO.2009.27.4449	journal	June 2010
Regional Hypoxia in Glioblastoma Multiforme Quantified with [ ¹⁸ F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival Spence, Alexander M.; Muzi, Mark; Swanson, Kristin R. Clinical Cancer Research, Vol. 14, Issue 9 https://doi.org/10.1158/1078-0432.CCR-07-4995	journal	May 2008
Role of Glutamine in Cancer: Therapeutic and Imaging Implications Rajagopalan, K. N.; DeBerardinis, R. J. Journal of Nuclear Medicine, Vol. 52, Issue 7 https://doi.org/10.2967/jnumed.110.084244	journal	June 2011
Glutamine and cancer: cell biology, physiology, and clinical opportunities Hensley, Christopher T.; Wasti, Ajla T.; DeBerardinis, Ralph J. Journal of Clinical Investigation, Vol. 123, Issue 9 https://doi.org/10.1172/JCI69600	journal	September 2013
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Wise, D. R.; DeBerardinis, R. J.; Mancuso, A. Proceedings of the National Academy of Sciences, Vol. 105, Issue 48 https://doi.org/10.1073/pnas.0810199105	journal	November 2008
Preparation and Characterization of L-[5-11C]-Glutamine for Metabolic Imaging of Tumors Qu, W.; Oya, S.; Lieberman, B. P. Journal of Nuclear Medicine, Vol. 53, Issue 1 https://doi.org/10.2967/jnumed.111.093831	journal	December 2011
PET Imaging of Glutaminolysis in Tumors by ¹⁸ F-( 2S,4R )4-Fluoroglutamine Lieberman, Brian P.; Ploessl, Karl; Wang, Limin Journal of Nuclear Medicine, Vol. 52, Issue 12 https://doi.org/10.2967/jnumed.111.093815	journal	November 2011
[ ¹⁸ F](2 S ,4 S )-4-(3-Fluoropropyl)glutamine as a Tumor Imaging Agent Wu, Zehui; Zha, Zhihao; Li, Genxun Molecular Pharmaceutics, Vol. 11, Issue 11 https://doi.org/10.1021/mp500236y	journal	April 2014
Specific PET Imaging of x _C ⁻ Transporter Activity Using a ¹⁸ F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism Koglin, Norman; Mueller, Andre; Berndt, Mathias Clinical Cancer Research, Vol. 17, Issue 18 https://doi.org/10.1158/1078-0432.CCR-11-0687	journal	July 2011
Exploratory Clinical Trial of (4 S )-4-(3-[ ¹⁸ F]fluoropropyl)-l-glutamate for Imaging x _C ⁻ Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer Baek, Sora; Choi, Chang-Min; Ahn, Sei Hyun Clinical Cancer Research, Vol. 18, Issue 19 https://doi.org/10.1158/1078-0432.CCR-12-0214	journal	August 2012
(4 S )-4-(3- ¹⁸ F-Fluoropropyl)-l-Glutamate for Imaging of x _C ^¯ Transporter Activity in Hepatocellular Carcinoma Using PET: Preclinical and Exploratory Clinical Studies Baek, Sora; Mueller, Andre; Lim, Young-Suk Journal of Nuclear Medicine, Vol. 54, Issue 1 https://doi.org/10.2967/jnumed.112.108704	journal	December 2012
Radiopeptides for Imaging and Therapy: A Radiant Future Chatalic, Kristell L. S.; Kwekkeboom, Dik J.; de Jong, Marion Journal of Nuclear Medicine, Vol. 56, Issue 12 https://doi.org/10.2967/jnumed.115.161158	journal	October 2015
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments Bison, Sander M.; Konijnenberg, Mark W.; Melis, Marleen Clinical and Translational Imaging, Vol. 2, Issue 1 https://doi.org/10.1007/s40336-014-0054-2	journal	February 2014
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours: Management impact of GaTate PET/CT Hofman, Michael S.; Kong, Grace; Neels, Oliver C. Journal of Medical Imaging and Radiation Oncology, Vol. 56, Issue 1 https://doi.org/10.1111/j.1754-9485.2011.02327.x	journal	February 2012
Advances in Peptide Receptor Radionuclide Therapy Sabet, Amir; Biersack, Hans-Jürgen; Ezziddin, Samer Seminars in Nuclear Medicine, Vol. 46, Issue 1 https://doi.org/10.1053/j.semnuclmed.2015.09.005	journal	January 2016
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Lütje, Susanne; Heskamp, Sandra; Cornelissen, Alexander S. Theranostics, Vol. 5, Issue 12 https://doi.org/10.7150/thno.13348	journal	January 2015
CXCR4-Based Imaging Agents Woodard, Lauren E.; Nimmagadda, Sridhar Journal of Nuclear Medicine, Vol. 52, Issue 11 https://doi.org/10.2967/jnumed.111.097733	journal	November 2011
Imaging agents for the chemokine receptor 4 (CXCR4) Kuil, Joeri; Buckle, Tessa; van Leeuwen, Fijs W. B. Chemical Society Reviews, Vol. 41, Issue 15 https://doi.org/10.1039/c2cs35085h	journal	January 2012
Molecular Imaging of Chemokine Receptor CXCR4 Weiss, Ido. D.; Jacobson, Orit Theranostics, Vol. 3, Issue 1 https://doi.org/10.7150/thno.4835	journal	January 2013
In vivo molecular imaging of chemokine receptor CXCR 4 expression in patients with advanced multiple myeloma Philipp‐Abbrederis, Kathrin; Herrmann, Ken; Knop, Stefan EMBO Molecular Medicine, Vol. 7, Issue 4 https://doi.org/10.15252/emmm.201404698	journal	March 2015
PET/CT imaging in cancer: Current applications and future directions: PET-CT Imaging in Cancer Farwell, Michael D.; Pryma, Daniel A.; Mankoff, David A. Cancer, Vol. 120, Issue 22 https://doi.org/10.1002/cncr.28860	journal	June 2014
Hallmarks of Cancer: The Next Generation Hanahan, Douglas; Weinberg, Robert A. Cell, Vol. 144, Issue 5 https://doi.org/10.1016/j.cell.2011.02.013	journal	March 2011
Tumor suppressors and cell metabolism: a recipe for cancer growth Jones, R. G.; Thompson, C. B. Genes & Development, Vol. 23, Issue 5 https://doi.org/10.1101/gad.1756509	journal	March 2009
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors Demetri, George D.; von Mehren, Margaret; Blanke, Charles D. New England Journal of Medicine, Vol. 347, Issue 7 https://doi.org/10.1056/NEJMoa020461	journal	August 2002
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®) Stroobants, S.; Goeminne, J.; Seegers, M. European Journal of Cancer, Vol. 39, Issue 14 https://doi.org/10.1016/S0959-8049(03)00073-X	journal	September 2003
The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging Van den Abbeele, Annick D. The Oncologist, Vol. 13, Issue S2 https://doi.org/10.1634/theoncologist.13-S2-8	journal	April 2008
¹⁸ F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO Gebhart, Geraldine; Gámez, Cristina; Holmes, Eileen Journal of Nuclear Medicine, Vol. 54, Issue 11 https://doi.org/10.2967/jnumed.112.119271	journal	October 2013
TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer Connolly, Roisin M.; Leal, Jeffrey P.; Goetz, Matthew P. Journal of Nuclear Medicine, Vol. 56, Issue 1 https://doi.org/10.2967/jnumed.114.144741	journal	December 2014
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial Coudert, Bruno; Pierga, Jean-Yves; Mouret-Reynier, Marie-Ange The Lancet Oncology, Vol. 15, Issue 13 https://doi.org/10.1016/S1470-2045(14)70475-9	journal	December 2014
Imaging of Cell Proliferation: Status and Prospects Bading, James R.; Shields, Anthony F. Journal of Nuclear Medicine, Vol. 49, Issue Suppl 2 https://doi.org/10.2967/jnumed.107.046391	journal	June 2008
PET imaging of cellular proliferation Mankoff, David A.; Shields, Anthony F.; Krohn, Kenneth A. Radiologic Clinics of North America, Vol. 43, Issue 1 https://doi.org/10.1016/j.rcl.2004.09.005	journal	January 2005
[ ¹⁸ F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung Sohn, Hee-Jung; Yang, You-Jung; Ryu, Jin-Sook Clinical Cancer Research, Vol. 14, Issue 22 https://doi.org/10.1158/1078-0432.CCR-08-0312	journal	November 2008
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Giaccone, Giuseppe; Herbst, Roy S.; Manegold, Christian Journal of Clinical Oncology, Vol. 22, Issue 5 https://doi.org/10.1200/JCO.2004.08.001	journal	March 2004
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Herbst, Roy S.; Giaccone, Giuseppe; Schiller, Joan H. Journal of Clinical Oncology, Vol. 22, Issue 5 https://doi.org/10.1200/JCO.2004.07.215	journal	March 2004
Rethinking clinical trials for cytostatic drugs Millar, Andrew W.; Lynch, Kevin P. Nature Reviews Cancer, Vol. 3, Issue 7 https://doi.org/10.1038/nrc1124	journal	July 2003
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko New England Journal of Medicine, Vol. 362, Issue 25 https://doi.org/10.1056/NEJMoa0909530	journal	June 2010
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography Kenny, Laura; Coombes, R. Charles; Vigushin, David M. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 9 https://doi.org/10.1007/s00259-007-0379-4	journal	March 2007
A Phase II Study of 3′-Deoxy-3′- ¹⁸ F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 Kostakoglu, Lale; Duan, Fenghai; Idowu, Michael O. Journal of Nuclear Medicine, Vol. 56, Issue 11 https://doi.org/10.2967/jnumed.115.160663	journal	September 2015
Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use Weber, Wolfgang A.; Petersen, Volker; Schmidt, Burkhard Journal of Clinical Oncology, Vol. 21, Issue 14 https://doi.org/10.1200/JCO.2003.12.004	journal	July 2003
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer Mac Manus, Michael P.; Hicks, Rodney J.; Matthews, Jane P. Journal of Clinical Oncology, Vol. 21, Issue 7 https://doi.org/10.1200/JCO.2003.07.054	journal	April 2003
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Surbone, A.; Longo, D. L.; DeVita, V. T. Journal of Clinical Oncology, Vol. 6, Issue 12 https://doi.org/10.1200/JCO.1988.6.12.1832	journal	December 1988
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Cheson, Bruce D.; Horning, Sandra J.; Coiffier, Bertr Journal of Clinical Oncology, Vol. 17, Issue 4 https://doi.org/10.1200/JCO.1999.17.4.1244	journal	April 1999
Revised Response Criteria for Malignant Lymphoma Cheson, Bruce D.; Pfistner, Beate; Juweid, Malik E. Journal of Clinical Oncology, Vol. 25, Issue 5 https://doi.org/10.1200/JCO.2006.09.2403	journal	February 2007
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma Juweid, Malik E.; Stroobants, Sigrid; Hoekstra, Otto S. Journal of Clinical Oncology, Vol. 25, Issue 5 https://doi.org/10.1200/JCO.2006.08.2305	journal	February 2007
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F. Journal of Clinical Oncology, Vol. 32, Issue 27 https://doi.org/10.1200/JCO.2013.54.8800	journal	September 2014
[ ¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study Martelli, Maurizio; Ceriani, Luca; Zucca, Emanuele Journal of Clinical Oncology, Vol. 32, Issue 17 https://doi.org/10.1200/JCO.2013.51.7524	journal	June 2014
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Therasse, Patrick; Arbuck, Susan G.; Eisenhauer, Elizabeth A. JNCI: Journal of the National Cancer Institute, Vol. 92, Issue 3 https://doi.org/10.1093/jnci/92.3.205	journal	February 2000
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors Wahl, Richard L.; Jacene, Heather; Kasamon, Yvette Journal of Nuclear Medicine, Vol. 50, Issue Suppl 1 https://doi.org/10.2967/jnumed.108.057307	journal	April 2009
Measuring response in a post-RECIST world: from black and white to shades of grey Michaelis, Laura C.; Ratain, Mark J. Nature Reviews Cancer, Vol. 6, Issue 5 https://doi.org/10.1038/nrc1883	journal	May 2006
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) McShane, Lisa M.; Altman, Douglas G.; Sauerbrei, Willi JNCI: Journal of the National Cancer Institute, Vol. 97, Issue 16 https://doi.org/10.1093/jnci/dji237	journal	August 2005
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting McShane, Lisa M.; Hayes, Daniel F. Journal of Clinical Oncology, Vol. 30, Issue 34 https://doi.org/10.1200/JCO.2012.42.6858	journal	December 2012

Cited By (4)

Two-Photon Fluorescence Imaging and Therapy of Cancer Cells with Anisotropic Gold-Nanoparticle-Supported Porous Silicon Nanostructures Chaix, Arnaud; Rajoua, Khalil; Stojanovic, Vanja ChemNanoMat, Vol. 4, Issue 4 https://doi.org/10.1002/cnma.201700368	journal	January 2018
Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics Fan, Wenpei; Tang, Wei; Lau, Joseph Advanced Materials, Vol. 31, Issue 12 https://doi.org/10.1002/adma.201806381	journal	January 2019
Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology Mankoff, David A.; Pantel, Austin R.; Viswanath, Varsha Current Pathobiology Reports, Vol. 7, Issue 3 https://doi.org/10.1007/s40139-019-00202-9	journal	July 2019
Automated One-pot Radiosynthesis of [11C]S-adenosyl Methionine Zoppolo, Florencia; Porcal, Williams; Oliver, Patricia Current Radiopharmaceuticals, Vol. 10, Issue 3 https://doi.org/10.2174/1874471010666170718171441	journal	November 2017

Similar Records

UW Translational Imaging Biomarker and Therapeutic Development

Technical Report · Fri Aug 31 00:00:00 EDT 2018 · OSTI ID:1462353

Minoshima, Satoshi; Krohn, Ken; Wilbur, Scott; +13 more

PET/CT in radiation oncology

Journal Article · Sat Nov 15 00:00:00 EST 2008 · Medical Physics · OSTI ID:1462353

Pan, Tinsu; Mawlawi, Osama

Comparison of Two Site-Specifically ¹⁸ F-Labeled Affibodies for PET Imaging of EGFR Positive Tumors

Journal Article · Mon Jul 14 00:00:00 EDT 2014 · Molecular Pharmaceutics · OSTI ID:1462353

Su, Xinhui; Cheng, Kai; Jeon, Jongho; +7 more

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
Cancer biomarkers
Positron emission tomography
Clinical trials

Title: Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers

Citation Formats

References (87)

Cited By (4)

Similar Records

Related Subjects